Loading...
XSHE
002907
Market cap883mUSD
Jul 10, Last price  
14.18CNY
1D
-1.25%
1Q
0.07%
IPO
97.77%
Name

Chongqing Pharscin Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002907 chart
P/E
90.98
P/S
7.16
EPS
0.16
Div Yield, %
0.59%
Shrs. gr., 5y
0.80%
Rev. gr., 5y
-0.45%
Revenues
827m
+6.75%
347,366,000425,904,327469,319,111551,667,000592,095,363703,415,290842,064,017882,474,476846,141,123846,141,123785,182,813785,182,813691,542,793774,819,866827,144,563
Net income
65m
-15.17%
28,947,00058,754,67973,836,22295,707,732111,987,477137,371,816169,746,083119,187,20291,780,35891,780,36198,400,63598,400,63832,699,15176,730,22765,086,781
CFO
62m
-61.53%
47,338,00020,221,00066,101,00057,733,00081,340,00031,795,00065,916,000113,638,00082,851,00013,045,000219,341,000161,767,00062,239,822
Dividend
Sep 09, 20250.035 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Chongqing Pharscin Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company actively involved in the research, development, manufacturing, and distribution of medicines. Its product portfolio encompasses a broad spectrum of pharmaceutical formulations, such as tablets, powders, granules, hard and soft capsules, alongside various injectables including powder, freeze-dried powder, and small volume injections. The company also specializes in active pharmaceutical ingredient (API) synthesis. This diverse range of products targets critical therapeutic areas, including the central nervous system (CNS), digestive health, otolaryngology, oncology, as well as cardiovascular and cerebrovascular conditions. Established in 1996, the company maintains its headquarters in Chongqing, China.
URL
http://www.pharscin.com/
IPO date
Oct 20, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT